Zepzelca (lurbinectedin) / PharmaMar, Jazz 
Welcome,         Profile    Billing    Logout  
 26 Diseases   31 Trials   31 Trials   1838 News 


«12345678910111213...1718»
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial primary completion date, Real-world evidence, Real-world effectiveness, Real-world:  LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) -  Aug 10, 2022   
    P=N/A,  N=200, Recruiting, 
    Trial primary completion date: Jun 2022 --> Nov 2022
  • ||||||||||  Review, Journal:  A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC). (Pubmed Central) -  Aug 2, 2022   
    The preferred decades-old first line regimen was etoposide-platinum, to which ≥50% of patients respond, followed by decades-old, tired topotecan in second line for platinum sensitive patients, full stop, because there were no approved therapeutic options (nor generally any compelling experimental ones) in third line or beyond...A significant sea change occurred in 2018 with the approval of nivolumab followed by pembrolizumab and atezolizumab in 2019, durvalumab in 2020, accelerated approval for lurbinectedin in 2020 and trilaciclib in 2021 for myelosuppression...Suddenly, a tumor type, whose name was virtually synonymous with stalled progress and movement, and which was much less well studied and funded than its more prevalent cousin, non-small cell lung cancer (NSCLC), finds itself in the eye of the storm, that is, at the epicenter of an intense flurry and ferment of activity, not all of it positive. This review surveys approved drugs and select up-and-coming ones in development for extensive stage SCLC.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  EMERGE 402: To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) -  Jun 30, 2022   
    P=N/A,  N=300, Recruiting, 
    Lurbinectedin could represent a valuable addition to therapies for ES, and is currently being evaluated in combination with irinotecan in advanced ES in a phase Ib/II trial. Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment open, Real-world evidence, Real-world effectiveness, Real-world:  LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) -  Jun 30, 2022   
    P=N/A,  N=200, Recruiting, 
    Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 Not yet recruiting --> Recruiting